# Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

> **NCT01987375** · PHASE1 · TERMINATED · sponsor: **Eben Rosenthal** · enrollment: 1 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Cetuximab-IRDye800

## Key facts

- **NCT ID:** NCT01987375
- **Lead sponsor:** Eben Rosenthal
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2017-04-19
- **Final completion:** 2017-04-19
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** logistics
- **Last updated:** 2019-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01987375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01987375, "Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01987375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*